A Phase 1 interventional study of acalabrutinib in Multiple Myeloma (MM), sponsored by Acerta Pharma BV. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-31.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Multiple Myeloma by AstraZeneca — 8 open to participants now, 8 under way, 3 of them phase 3. Multiple Myeloma · AstraZeneca.
Among the 16 studies in Multiple Myeloma by AstraZeneca, this one is the 14th largest by enrollment, is one of 2 that started in 2015, is one of 6 in phase 1, and was the 2nd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →8 of the 16 studies in Multiple Myeloma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Australia, Brazil and 15 more countries
Ages 18–130
AstraZeneca · Sites in United States, Australia
Ages 18+
AstraZeneca · Sites in United States, Australia, Brazil and 12 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Brazil and 12 more countries
Ages 18+
AstraZeneca · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 7 · Phase 3 3
First in 2008; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 104 across the 16 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
1 of the studies in Multiple Myeloma by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05850234AstraZenecaAZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Multiple Myeloma by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acalabrutinib 100 mg twice daily (bid) continuously
Drug: acalabrutinib
Acalabrutinib 100 mg bid continuously and 40 mg dexamethasone once weekly
Drug: acalabrutinib
Also known as: ACP-196
Safety Profile of Acalabrutinib With and Without Dexamethasone
AEs and SAEs were coded by system organ class (SOC) and preferred term (PT) based on the Medical Dictionary for Regulatory Activities (MedDRA) reporting system. All AEs summarized were treatment-emergent. Summaries were also presented by the severity of the AE (per Common Toxicity Criteria for Adverse Events \[CTCAE\]) and by relationship to study drug as assessed by the investigator. Events of clinical interest (ECIs) selected for dedicated analysis were evaluated using Standardized MedDRA Queries, where available, by SOC, or by Sponsor-defined baskets of MedDRA Adverse Event Grouped Terms (AEGTs). The following ECIs were summarized: Cardiac events (including a subset of atrial fibrillation), cytopenias (anemia, leukopenia, neutropenia, and thrombocytopenia), hemorrhage (including a subset of major hemorrhage), hepatic events, hypertension, infection, interstitial lung disease/pneumonitis, second primary malignancies (second primary malignancies excluding skin), tumor lysis syndrome.
Time frame: From first dose of study drug up to Cycle 12 (48 weeks). Subjects who showed benefit from study drugs were allowed to continue until disease progression.
Pharmacokinetic (PK) Parameters Calculated for Acalabrutinib: AUC0-4, AUClast, AUCINF, Cmax, Tmax, λz, t1/2, CL/F, and Vz/F. PK Parameters Calculated for Dexamethasone: Tmax, Cmax, AUC0-4 and AUClast.
The plasma PK of study drug was characterized using noncompartmental analysis. PK parameters were calculated whenever possible, from plasma concentrations of acalabrutinib. Missing dates or times could have been imputed for PK and pharmacodynamic (PD) samples if the missing values could be established with an acceptable level of accuracy based on other information obtained during the visit in question. If PK and PD sampling for a 33 Final Clinical Study Report Drug Substance Acalabrutinib Study Code ACE-MY-001 Edition Number 2 Date 31 October 2018 given subject was not performed according to protocol, the subject could have been excluded from the PK and PD analyses. The PK parameters were tabulated and summarized using descriptive statistics. For each PD variable, the concentration at each assessment was described. The change from baseline to each assessment was summarized. As appropriate the on treatment values were compared with the pretreatment baseline values using paired t-tests.
Time frame: On Days 1 and 22: pre-dose, and at 0.5, 0.75, 1, 2, 4, and 6 hours after the morning dose. On Days 8, 15, and 28: pre-dose and 1 hour after the morning dose.
Bruton Tyrosine Kinase (BTK) Occupancy
The percent occupied BTK was calculated in each subject's peripheral blood mononuclear cells (PBMC) sample for each assessment timepoint using an ELISA-based method. Samples from 17 subjects met the criteria for data inclusion, having a dynamic range (signal to noise) of ≥5 for the Day 1 pre-dose timepoint. Acalabrutinib administered at 100 mg bid resulted in a median steady-state (Day 8) BTK target occupancy level of 95% and 98% for Cohort 1 and Cohort 2, respectively. The Days 28 and 56 assessments, both taken at pre-dose, were \>97% occupancy for each cohort. Intersubject variability was low, with 6 of 7 (86%) subjects in Cohort 1 and 4 of 5 (80%) subjects in Cohort 2 having \>90% BTK occupancy at steady-state trough (12h post-dose). The single subject in Cohort 2 with \<90% occupancy at Day 8 pre-dose did not take their Day 7 doses.
Time frame: On Days 1 and 8: pre-dose and at 4 hours after the morning dose. On Days 28 and 56: morning pre-dose only.
Response Assessed According to Guidelines Proposed by the International Myeloma Workshop Consensus Panel and European Group for Blood and Marrow Transplant
Per EBMT: CR, negative immunofixation of serum and urine, disappearance of plasmacytomas and \< 5% plasma cells; Stringent complete response (SCR), CR + normal flow cytometry and absence of clonal plasma cells; Very good partial response (VGPR), Serum and urine M-protein detectable on immunofixation but not on electrophoresis or \> 90% reduction is serum and urine M protein; Partial response (PR), \> 50% reduction in serum M-protein and \> 90% reduction in 24 hour urine M-protein, \> 50% reduction in baseline soft tissue plasmacytoma; Minimal response (MR), 25-49% reduction of serum M-protein and 50-59% reduction in 24 hour urine M-protein, 25-49% reduction in plasmacytomas and no increase in lytic bone lesions; Stable disease (SD), not meeting criteria for CR, VGPR, MR, PR or progressive disease (PD); PD, increase of 25% or more from nadir in serum M-protein, urine M-protein, new or increased bone lesions or plasmacytomas, or hypercalcemia solely attributed to multiple myeloma.
Time frame: From first dose of study drug up to Cycle 12 (48 weeks). Subjects who showed benefit from study drugs were allowed to continue until disease progression
Multicenter, open-label, randomized, parallel-group study to evaluate the safety, pharmacokinetics, pharmacodynamics and activity of acalabrutinib with/without dexamethasone in subjects with relapsed/refractory multiple myeloma in US and United Kingdom. 27 subjects enrolled into 2 cohorts. Enrollment was discontinued because of lack of efficacy.
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 13 | 14 |
| Completed | 11 | 8 |
| Not completed | 2 | 6 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Started another cancer therapy | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: In agreement with patient, no benefit | 0 | 1 |
AEs and SAEs were coded by system organ class (SOC) and preferred term (PT) based on the Medical Dictionary for Regulatory Activities (MedDRA) reporting system. All AEs summarized were treatment-emergent. Summaries were also presented by the severity of the AE (per Common Toxicity Criteria for Adverse Events \[CTCAE\]) and by relationship to study drug as assessed by the investigator. Events of clinical interest (ECIs) selected for dedicated analysis were evaluated using Standardized MedDRA Queries, where available, by SOC, or by Sponsor-defined baskets of MedDRA Adverse Event Grouped Terms (AEGTs). The following ECIs were summarized: Cardiac events (including a subset of atrial fibrillation), cytopenias (anemia, leukopenia, neutropenia, and thrombocytopenia), hemorrhage (including a subset of major hemorrhage), hepatic events, hypertension, infection, interstitial lung disease/pneumonitis, second primary malignancies (second primary malignancies excluding skin), tumor lysis syndrome.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Treatment-emergent adverse events (TEAE) | 13 | 14 |
| Treatment-related TEAE | 7 | 7 |
| SAE | 5 | 9 |
| Treatment-related SAE | 1 | 2 |
| TEAE leading to actions taken on study drug | 1 | 8 |
The plasma PK of study drug was characterized using noncompartmental analysis. PK parameters were calculated whenever possible, from plasma concentrations of acalabrutinib. Missing dates or times could have been imputed for PK and pharmacodynamic (PD) samples if the missing values could be established with an acceptable level of accuracy based on other information obtained during the visit in question. If PK and PD sampling for a 33 Final Clinical Study Report Drug Substance Acalabrutinib Study Code ACE-MY-001 Edition Number 2 Date 31 October 2018 given subject was not performed according to protocol, the subject could have been excluded from the PK and PD analyses. The PK parameters were tabulated and summarized using descriptive statistics. For each PD variable, the concentration at each assessment was described. The change from baseline to each assessment was summarized. As appropriate the on treatment values were compared with the pretreatment baseline values using paired t-tests.
| percentage of CV | Cohort 1 - Day 1 | Cohort 2 - Day 1 | Cohort 1 - Day 22 | Cohort 2 - Day 22 |
|---|---|---|---|---|
| Cmax (ng/mL) - the maximum concentration observed | 524 ± 112 | 437 ± 91.5 | 271 ± 103 | 607 ± 90.8 |
| AUC (area under the curve)_0-4 (hr*ng/mL) | 604 ± 72.9 | 621 ± 64 | 390 ± 105 | 766 ± 60.5 |
| AUC_last (hr*ng/mL) | 638 ± 69.5 | 675 ± 56.9 | 423 ± 102 | 812 ± 58.3 |
| AUC_INF (infinity) (hr*ng/mL) | 754 ± 67.8 | 732 ± 63.1 | 411 ± 111 | 826 ± 62.6 |
The percent occupied BTK was calculated in each subject's peripheral blood mononuclear cells (PBMC) sample for each assessment timepoint using an ELISA-based method. Samples from 17 subjects met the criteria for data inclusion, having a dynamic range (signal to noise) of ≥5 for the Day 1 pre-dose timepoint. Acalabrutinib administered at 100 mg bid resulted in a median steady-state (Day 8) BTK target occupancy level of 95% and 98% for Cohort 1 and Cohort 2, respectively. The Days 28 and 56 assessments, both taken at pre-dose, were \>97% occupancy for each cohort. Intersubject variability was low, with 6 of 7 (86%) subjects in Cohort 1 and 4 of 5 (80%) subjects in Cohort 2 having \>90% BTK occupancy at steady-state trough (12h post-dose). The single subject in Cohort 2 with \<90% occupancy at Day 8 pre-dose did not take their Day 7 doses.
| percentage of occupied BTK | Cohort 1 - Day 1 Pre | Cohort 2 - Day 1 Pre | Cohort 1 - Day 1 Post | Cohort 2 - Day 1 Post | Cohort 1 - Day 8 Pre | Cohort 2 - Day 8 Pre | Cohort 1 - Day 8 Post | Cohort 2 - Day 8 Post | Cohort 1 - Day 28 Pre | Cohort 2 - Day 28 Pre | Cohort 1 - Day 56 Pre | Cohort 2 - Day 56 Pre |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bruton Tyrosine Kinase (BTK) Occupancy | 0 ± 0 | 0 ± 0 | 98.5 ± 0.9 | 98.5 ± 1.3 | 93.2 ± 6.6 | 94.3 ± 8.8 | 98.6 ± 1.1 | 96.8 ± 4.8 | 97.6 ± 1.8 | 95.8 ± 5.5 | 95.7 ± 6.2 | 97.6 ± 1.3 |
Per EBMT: CR, negative immunofixation of serum and urine, disappearance of plasmacytomas and \< 5% plasma cells; Stringent complete response (SCR), CR + normal flow cytometry and absence of clonal plasma cells; Very good partial response (VGPR), Serum and urine M-protein detectable on immunofixation but not on electrophoresis or \> 90% reduction is serum and urine M protein; Partial response (PR), \> 50% reduction in serum M-protein and \> 90% reduction in 24 hour urine M-protein, \> 50% reduction in baseline soft tissue plasmacytoma; Minimal response (MR), 25-49% reduction of serum M-protein and 50-59% reduction in 24 hour urine M-protein, 25-49% reduction in plasmacytomas and no increase in lytic bone lesions; Stable disease (SD), not meeting criteria for CR, VGPR, MR, PR or progressive disease (PD); PD, increase of 25% or more from nadir in serum M-protein, urine M-protein, new or increased bone lesions or plasmacytomas, or hypercalcemia solely attributed to multiple myeloma.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| sCR | 0 | 0 |
| CR | 0 | 0 |
| VGPR | 0 | 0 |
| PR | 0 | 0 |
| MR | 1 | 2 |
| SD | 5 | 6 |
| PD | 4 | 1 |
| NE (not evaluable) | 3 | 5 |
Collected over Reported Adverse Events (AEs) include events starting on or after Day 0 and on or before Day 1210.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 2/13 (15.4%) | 5/13 (38.5%) | 13/13 (100%) |
| Cohort 2 | 4/14 (28.6%) | 9/14 (64.3%) | 14/14 (100%) |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| HypercalcaemiaMetabolism and nutrition disorders | 1/13 | 1/14 |
| Hyperviscosity syndromeBlood and lymphatic system disorders | 1/13 | 0/14 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/13 | 0/14 |
| PainGeneral disorders | 1/13 | 0/14 |
| SepsisInfections and infestations | 1/13 | 0/14 |
| Skin massSkin and subcutaneous tissue disorders | 1/13 | 0/14 |
| Urinary tract infectionInfections and infestations | 1/13 | 0/14 |
| Acute kidney injuryRenal and urinary disorders | 0/13 | 1/14 |
| Angina pectorisCardiac disorders | 0/13 | 1/14 |
| BacteraemiaInfections and infestations | 0/13 | 1/14 |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 7/13 | 6/14 |
| DiarrhoeaGastrointestinal disorders | 6/13 | 6/14 |
| HeadacheNervous system disorders | 6/13 | 4/14 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/13 | 4/14 |
| FatigueGeneral disorders | 4/13 | 2/14 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/13 | 0/14 |
| Back painMusculoskeletal and connective tissue disorders | 1/13 | 4/14 |
| NauseaGastrointestinal disorders | 3/13 | 3/14 |
| ContusionPsychiatric disorders | 3/13 | 1/14 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 3/13 | 1/14 |
| Age, Categorical(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 4 | 13 |
| >=65 years | 4 | 10 | 14 |
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Median | 60.0 (49 to 83) | 68.5 (53 to 78) | 65.0 (49 to 83) |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Female | 6 | 4 | 10 |
| Male | 7 | 10 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 11 | 14 | 25 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 5 |
| White | 11 | 9 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| United States | 6 | 7 | 13 |
| United Kingdom | 7 | 7 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2015 to primary completion in Apr 2019, 50 months.
Results were first posted in May 2020, 1 year after primary completion.
Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 50 months is above that.
Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib